Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo.

[1]  J. Eidt,et al.  Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.

[2]  M. Rosolowsky,et al.  Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. , 1989, Circulation.

[3]  V. Fuster,et al.  Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. , 1988, Circulation.

[4]  J. Willerson,et al.  Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. , 1988, Circulation.

[5]  M. Josephson,et al.  Effects of verapamil and diltiazem on human platelet function. , 1987, The American journal of physiology.

[6]  W. Campbell,et al.  Inhibition of Cyclic Flow Variations in Stenosed Canine Coronary Arteries by Thromboxane A2/Prostaglandin H2 Receptor Antagonists , 1986, Circulation research.

[7]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[8]  L Morgenstern,et al.  Coronary angioscopy in patients with unstable angina pectoris. , 1986, The New England journal of medicine.

[9]  M. Winniford,et al.  Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. , 1986, Journal of the American College of Cardiology.

[10]  H. Goldsmith,et al.  Rheological Aspects of Thrombosis and Haemostasis: Basic Principles and Applications , 1986, Thrombosis and Haemostasis.

[11]  V. Fuster,et al.  Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model , 1986, Arteriosclerosis.

[12]  C. Benedict,et al.  Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. , 1986, Circulation.

[13]  R. Fuller,et al.  Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists. , 1985, The Journal of pharmacology and experimental therapeutics.

[14]  H C Smith,et al.  Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina. , 1985, Journal of the American College of Cardiology.

[15]  M. Ogletree,et al.  Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. , 1985, The Journal of pharmacology and experimental therapeutics.

[16]  J. Willerson,et al.  Effects of propranolol and diltiazem alone and in combination on the recovery of left ventricular segmental function after temporary coronary occlusion and long-term reperfusion in conscious dogs. , 1985, Circulation.

[17]  M. Marcus,et al.  Removal of the Endothelium Potentiates Canine Large Coronary Artery Constrictor Responses to 5‐Hydroxytryptamine in Vivo , 1985, Circulation research.

[18]  R. Abbate,et al.  Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. , 1985, American heart journal.

[19]  Louis E. Teichholz,et al.  Angiographie morphology and the pathogenesis of unstable angina pectoris , 1985 .

[20]  Marlene L. Cohen,et al.  Receptor specificity of the 5HT2 receptor antagonist, LY53857 , 1985 .

[21]  S L Winters,et al.  Angiographic morphology and the pathogenesis of unstable angina pectoris. , 1985, Journal of the American College of Cardiology.

[22]  W. Campbell,et al.  The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. , 1984, Circulation research.

[23]  J. Pieper,et al.  Effects of diltiazem, dipyridamole, and their combination on hemostasis , 1984, Clinical pharmacology and therapeutics.

[24]  G. FitzGerald,et al.  The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. , 1984, Circulation.

[25]  W. Campbell,et al.  Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. , 1984, Circulation.

[26]  S. Kristensen,et al.  Nitroglycerin prolongs the bleeding time in healthy males. , 1983, Thrombosis research.

[27]  Vatner Sf,et al.  Comparison of effects of nifedipine and nitroglycerin on large and small coronary arteries and cardiac function in conscious dogs. , 1983 .

[28]  T. Morita,et al.  Inhibition of Platelet Aggregation by Diltiazem: Comparison with Verapamil and Nifedipine and Inhibitory Potencies of Diltiazem Metabolites , 1983, Circulation research.

[29]  S. Vatner,et al.  Comparison of Effects of Nifedipine and Nitroglycerin on Large and Small Coronary Arteries and Cardiac Function in Conscious Dogs , 1983, Circulation research.

[30]  E. Braunwald,et al.  Mechanism of action of calcium-channel-blocking agents. , 1982, The New England journal of medicine.

[31]  K. Gallagher,et al.  Blood Flow Reductions in Stenosed Canine Coronary Arteries: Vasospasm or Platelet Aggregation? , 1982, Circulation.

[32]  E. Bolson,et al.  The Mechanisms of Nitroglycerin Action: Stenosis Vasodilatation as a Major Component of the Drug Response , 1981, Circulation.

[33]  L. Hillis,et al.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.

[34]  E. Antman,et al.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. , 1980, Annals of internal medicine.

[35]  J. Abrams.  Nitroglycerin and long-acting nitrates. , 1980, The New England journal of medicine.

[36]  R. Alexander,et al.  Inhibition of platelet function by organic nitrate vasodilators. , 1980, Blood.

[37]  J. Mehta,et al.  Comparative Effects of Nitroprusside and Nitroglycerin on Platelet Aggregation in Patients with Heart Failure , 1980, Journal of cardiovascular pharmacology.

[38]  M Pagani,et al.  Alpha adrenergic vasoconstriction and nitroglycerin vasodilation of large coronary arteries in the conscious dog. , 1980, The Journal of clinical investigation.

[39]  M Pagani,et al.  Measurement of multiple simultaneous small dimensions and study of arterial pressure-dimension relations in conscious animals. , 1978, The American journal of physiology.

[40]  F. Murad,et al.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Schultz,et al.  Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens , 1977, Nature.

[42]  J. Oates,et al.  Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. , 1976, Science.

[43]  J. Folts,et al.  Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin , 1976, Circulation.

[44]  N. Ling,et al.  Synthesis and conformations of hypothalamic hormone releasing factors: two QRF-analogues containing backbone N-methyl groups , 1975, Nature.

[45]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Mcgregor,et al.  Effect of Coronary Vasodilator Drugs on Retrograde Flow in Areas of Chronic Myocardial Ischemia , 1964, Circulation research.